(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.27% ¥ 737.00
Live Chart Being Loaded With Signals
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL...
Stats | |
---|---|
Объем за сегодня | 183 500 |
Средний объем | 75 191.00 |
Рыночная капитализация | 40.21B |
EPS | ¥0 ( 2024-02-14 ) |
Дата следующего отчета о доходах | ( ¥0 ) 2024-05-10 |
Last Dividend | ¥13.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 29.94 |
ATR14 | ¥0.483 (0.07%) |
Объем Корреляция
Seikagaku Corporation Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Seikagaku Corporation Корреляция - Валюта/Сырье
Seikagaku Corporation Финансовые показатели
Annual | 2022 |
Выручка: | ¥33.46B |
Валовая прибыль: | ¥18.02B (53.87 %) |
EPS: | ¥40.48 |
FY | 2022 |
Выручка: | ¥33.46B |
Валовая прибыль: | ¥18.02B (53.87 %) |
EPS: | ¥40.48 |
FY | 2022 |
Выручка: | ¥34.85B |
Валовая прибыль: | ¥20.53B (58.90 %) |
EPS: | ¥66.32 |
FY | 2021 |
Выручка: | ¥27.66B |
Валовая прибыль: | ¥15.55B (56.21 %) |
EPS: | ¥75.54 |
Financial Reports:
No articles found.
Seikagaku Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥13.00 (N/A) |
¥0 (N/A) |
¥13.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥4.44 | 2004-03-26 |
Last Dividend | ¥13.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 40 | -- |
Total Paid Out | ¥437.61 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.38 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.53 | |
Div. Directional Score | 6.61 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8550.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7872.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7013.T | No Dividend Player | 2023-09-28 | Annually | 0 | 0.00% | |
6362.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
5233.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4324.T | Ex Dividend Junior | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
3488.T | Ex Dividend Junior | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
2726.T | Ex Dividend Junior | 2024-02-28 | Annually | 0 | 0.00% | |
9619.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8157.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0377 | 1.500 | 9.25 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0164 | 1.200 | 9.45 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0187 | 1.500 | -0.903 | -1.355 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.21 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.08 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.79 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00493 | -1.500 | 9.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 258.75 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00549 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.505 | 1.000 | 4.91 | 4.91 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0298 | 1.000 | -1.403 | -1.403 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 8.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.434 | 0.800 | -0.439 | -0.351 | [0.5 - 2] |
Total Score | 10.68 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 30.72 | 1.000 | 7.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0187 | 2.50 | -0.581 | -1.355 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.53 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -2.52 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0914 | 1.000 | -0.216 | 0 | [0.1 - 0.5] |
Total Score | 2.53 |
Seikagaku Corporation
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа